Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebrospinal Fluid Biomarkers in Normal Pressure Hydrocephalus
Aging, Dementia, and Behavioral Neurology
P5 - Poster Session 5 (8:00 AM-9:00 AM)
10-002
To evaluate the levels of cerebrospinal fluid (CSF) beta-amyloid1-42 (Aβ42), total tau (t-tau), and phospho-tau181 (p-tau) in a group of patients with suspected normal pressure hydrocephalus (NPH), Alzheimer’s disease (AD), and normal controls.

NPH is a condition with enlarged ventricles without marked elevation in CSF pressure.

There were 131 participants in this study: 

(a) Suspected-NPH: 72 participants with ventriculomegaly on MRI or CT with clinical symptoms of NPH. These participants were then divided into two groups of 1) Probable-NPH (38 participants) and 2) Unlikely-NPH (34 participants) based on whether participants experienced an improvement in their gait after removal of a large amount of CSF; (b) AD group: 30 participants with CSF biomarkers and cognitive symptoms consistent with AD; (c) Control group: 29 participants who were cognitively and functionally normal.

We found no significant difference between the levels of CSF biomarkers in the probable and unlikely-NPH group. Lower levels of CSF Aβ42 and p-tau were observed in the probable-NPH group compared to the normal controls (444.22±163.3 vs. 1213.75±556.5, p <0.001; and 26.05±9.2 vs. 46.16±13.3 pg/mL, p<0.001; respectively). Lower levels of CSF p-tau and t-tau were found in the probable-NPH group compared to the AD group (26.05±9.2 vs. 114.95±28.2, p<0.001; and 193.29±92.3 vs. 822.65±311.5 pg/mL, p<0.001; respectively) but the CSF Aβ42 was low in both the probable-NPH and AD group (p = 0.703). CSF Aβ42 levels correlated with age and Evans index only in the probable-NPH group (r=0.460, p=0.004; and r=- 0.530, p=0.001; respectively).
Although concentrations of p-tau and t-tau are significantly different between probable-NPH and AD subjects, low Aβ42 concentration is seen in both diseases. Probable-NPH subjects with higher Aβ42 values tended to be older in our study which supports the hypothesis that age-related atrophy results in better Aβ42 clearance in the CSF because of the increase in the interstitial space. 
Authors/Disclosures
Foad Taghdiri, MD, MSc (University of Toronto)
PRESENTER 		Dr. Taghdiri has nothing to disclose.
No disclosure on file
Alfonso Fasano, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Toronto Western Hospital - U of Toronto) Dr. Fasano has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Fasano has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Fasano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Fasano has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Fasano has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boston Scientific. Dr. Fasano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbott. Dr. Fasano has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fasano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceregate. Dr. Fasano has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Inbrain Neuroelectronics. Dr. Fasano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Syneos Health. Dr. Fasano has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Annovis. Dr. Fasano has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for CADTH. Dr. Fasano has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International Parkinson and Movement Disorders Society. The institution of Dr. Fasano has received research support from Boston Scientific. The institution of Dr. Fasano has received research support from Medtronic. The institution of Dr. Fasano has received research support from Abbvie. The institution of Dr. Fasano has received research support from Canadian Institutes of Health Research (CIHR). The institution of Dr. Fasano has received research support from Michael J Fox Foundation. The institution of Dr. Fasano has received research support from Bluerock Therapeutics. Dr. Fasano has received publishing royalties from a publication relating to health care. Dr. Fasano has a non-compensated relationship as a Medical Advisory Committee with CenteR for Advancing Neurological Innovation to Application (CRANIA) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Fasano has a non-compensated relationship as a Medical Advisory Committee with HopeNET that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Fasano has a non-compensated relationship as a Medical Advisory Committee with International Essential Tremor Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Fasano has a non-compensated relationship as a Member with Tremor Research Group that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Fasano has a non-compensated relationship as a Co-Chair with Tremor Study Group of the IPMDS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Fasano has a non-compensated relationship as a Vice-Chair with NPH Study Group of the IPMDS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Fasano has a non-compensated relationship as a Vice-Chair with Industry Committee of the IPMDS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Musleh A. Algarni, MBBS No disclosure on file
No disclosure on file
David F. Tang-Wai, MD, FRCPC (Toronto Western Hospital/University Health Network) Dr. Tang-Wai has nothing to disclose.
Carmela Tartaglia, MD (Toronto Western Hospital, University of Toronto) Dr. Tartaglia has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Tartaglia has received research support from NIH. The institution of Dr. Tartaglia has received research support from University of Toronto.